Purdue Pharma sued Collegium for infringement of U.S. Patent Nos. 9,522,919 and 9,073,933, which relate to oxycodone hydrochloride compositions and formulations. The suit is based on Collegium 2019s submission of a supplemental New Drug Application seeking approval for revised labeling for Collegium 2019s Xtampza 00ae oxycodone extended release capsules. Purdue has been pursuing claims against Xtampza 00ae for some time now, beginning in March 2015, and most recently on September 21, 2017, as discussed here.
By submitting this form, you are consenting to receive marketing emails from: Lando & Anastasi, LLP. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
SHARE THIS POST
